California
Biotech Insights

Biotech Market Update

ARCH Venture Partners targets $3 Billion raise for latest Fund, ADARx aims for IPO, Ionis wins FDA clearance

September 8, 2026

Recent Funding: Moonwalk Biosciences (SF) Raises $70M Series B to Test siRNA Obesity Treatment The genomic biotech closed a $70 million Series B co-led by Alpha Wave and YK Bioventures, with Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures participating. Proceeds will move lead obesity candidate MW101 — an adipose-targeted RNAi […]

Biotech Market Update

AusperBio completes $120M Series C, Electra files for IPO, FDA approves Revolution’s pancreatic cancer drug

September 1, 2026

Recent Funding: AusperBio (SF) Completes $120M Series C to Advance Hepatitis B Oligonucleotide Toward Commercialization Raised a $120M Series C led by RA Capital Management (with Qiming, HanKang, YuanBio, CDH and others) to push lead antisense oligonucleotide AHB-137 through Phase 3 and toward commercialization. AHB-137 is an unconjugated ASO designed to suppress hepatitis B viral […]

Biotech Market Update

BioMarin buys Alesta for $275M, Ultragenyx wins first-ever gene therapy approval

August 25, 2026

M&A, Deals, Partnerships: BioMarin (SF) Buys Alesta for $275M to Enter Rare Bone Disease Acquiring Alesta Therapeutics for $275M upfront plus up to $215M in milestones to gain ALE1, an oral small molecule for hypophosphatasia (a rare genetic bone disease), setting up a challenge to AstraZeneca’s enzyme therapy. ALE1 is in a Phase 1/2a trial; […]

Biotech Market Update

Khartis emerges from stealth with $95M, Skye combines with Redx to form Fibrx

August 18, 2026

Recent Funding: Epicrispr Biotechnologies (SF) Secures $90M Series C After Early FSHD Data The Series C brought in $90 million on the back of promising early clinical data for EPI-321, an epigenetic gene-silencing candidate for facioscapulohumeral muscular dystrophy (FSHD), under CEO Amber Salzman. The raise deepens the company’s bet on epigenetic editing — modifying gene […]

Biotech Leader Spotlight

Ben Buelow, CEO & Co-Founder of 92Bio

August 13, 2026

Ben Buelow is CEO and Co-Founder of 92Bio. Ben and the 92Bio team are bringing their industry leading expertise in therapeutic antibody discovery and development to create the next generation of multi-specific antibodies for the treatment of cancer. He previously served as CEO of Ancora Biotech (2022-2024) and Chief Medical Officer of Teneobio from 2016-2021, when it was acquired by Amgen. He has guided five antibodies from concept to clinic since 2016, with two now in phase 3 registrational trials. He has published ~25 peer-reviewed papers and has presented at numerous national and international scientific conferences. Ben completed his residency and surgical pathology fellowship as chief resident at UCSF in 2016. He received an MD with honors and a PhD in Immunology from the University of Washington in 2011.

Biotech Market Update

Expedition closes $115M Series B, aTyr cuts 60% of staff, Jazz to acquire Actio for $820M

August 11, 2026

Recent Funding: Expedition Therapeutics (SF) Closes $115M Series B for COPD Drug The oversubscribed round was led by General Atlantic with backing from Sanofi, funding the push of oral DPP1 inhibitor EXPD-101 into Phase 2 for chronic obstructive pulmonary disease. The company dosed the first patient in that Phase 2 trial alongside the raise, following […]

California Biotech Insights

California
Biotech Insights